Program overview
Context
Indication: Cutaneous Squamous Cell Carcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: Melanoma Institute Australia
Watchlist Signal
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination is flagged as watchlist signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06288191
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06288191 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | rare_population_signal | strict_eligibility_signal |